Observational studyBMC infectious diseases2026
Hepatitis C care cascade using direct-acting antivirals in rural new York State from 2013 to 2023: a retrospective observational study.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHepatitis C virus (HCV) infection rates are higher in rural areas than in urban areas, yet rural HCV care remains understudied. We evaluated the HCV care cascade using direct-acting antivirals (DAAs) in rural New York State.
methodsElectronic health record data from 2013 to 2023 were retrospectively collected from active Bassett Health Network primary care patients aged 18-79 years, consistent with the most recent US screening recommendations. We constructed 11 annual testing cohorts based upon the date of HCV serological testing. Annual care cascades were summarized using frequencies and percentages. We used chi-square to compare outcomes pre- and post-implementation of HCV RNA reflex testing and universal screening and to assess differences by opioid use disorder status.
resultsThe average annualized patient population was 72,615, White (96.45%) and male (44.58%). HCV seropositivity was highest (4.17%) among those aged 20-39 years. Annual HCV RNA positivity in HCV seropositive patients ranged from 18.27 to 76.60%. DAA initiation ranged from 26.32 to 56.52% in HCV RNA-positive patients. HCV antibody testing increased significantly after implementation of universal screening (p < 0.0001). Patients with opioid use disorder had higher RNA positivity (51.32% vs. 32.07%, p < 0.0001) and lower DAA initiation (35.65% vs. 57.71%, p < 0.0001) than those without opioid use disorder.
conclusionsWhile HCV diagnosis improved after universal screening implementation, DAA treatment remains suboptimal in rural New York State, especially among people with OUD. Expanding DAA treatment in people with opioid use disorder is critical to improving rural HCV care and HCV elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.